YWYe Wang

Ye Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ye Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Han Wang

    State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing, China

    1 shared publication
  • Min-Sheng Zhu

    State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing University, Nanjing, China

    1 shared publication
  • Tian-Tian Qiu

    State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University, Nanjing, China

    1 shared publication
  • Xin Chen

    State Key Laboratory of Pharmaceutical Biotechnology, National Resource Center for Mutant Mice, Department of Gastroenterology of Nanjing Drum Tower Hospital, and Suqian Scientific Research Institute, Medical School of Nanjing University, Nanjing, China

    1 shared publication
  • Xue-Na Zhang

    Suqian Scientific Research Institute of Nanjing University Medical School, Department of Gastroenterology and Central Laboratory of Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, 223800, Jiangsu, China

    1 shared publication
  • Yu-Wei Zhou

    Jiangsu Key Laboratory of Molecular Medicine, Department of Otolaryngology Head and Neck Surgery, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China

    1 shared publication

Latest Publications

  • Open Access

    Gallbladder dysfunction caused by MYPT1 ablation triggers cholestasis-induced hepatic fibrosis in mice

    by Ye Wang, Zhi-Hui Jiang, Yu-Wei Zhou, Tian-Tian Qiu, Han Wang, Min-Sheng Zhu, Xin Chen, Xue-Na Zhang

    Background: The incidence of gallbladder diseases is as high as 20%, but whether gallbladder diseases contribute to hepatic disorders remains unknown. Methods: Here, we established an animal model of gallbladder dysfunction and assessed the role of a diseased gallbladder in cholestasis-induced hepatic fibrosis (CIHF). Results: Mice with smooth muscle-specific deletion of Mypt1, the gene encoding the main regulatory subunit of myosin light chain phosphatase (myosin phosphatase target subunit 1 [MYPT1]), had apparent dysfunction of gallbladder motility. This dysfunction was evidenced by abnormal contractile responses, namely, inhibited cholecystokinin 8-mediated contraction and nitric oxide–resistant relaxation. As a consequence, the gallbladder displayed impaired bile filling and biliary tract dilation comparable to the alterations in CIHF. Interestingly, the mutant animals also displayed CIHF features, including necrotic loci by the age of 1 month and subsequently exhibited progressive fibrosis and hyperplastic/dilated bile ducts. This pathological progression was similar to the phenotypes of the animal model with bile duct ligation and patients with CIHF. The characteristic biomarker of CIHF, serum alkaline phosphatase activity, was also elevated in the mice. Moreover, we observed that the myosin phosphatase target subunit 1 protein level was able to be regulated by several reagents, including lipopolysaccharide, exemplifying the risk factors for gallbladder dysfunction and hence CIHF. Conclusions: We propose that gallbladder dysfunction caused by myosin phosphatase target subunit 1 ablation is sufficient to induce CIHF in mice, resulting in impairment of the bile transport system.